Literature DB >> 19073602

Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Kelly Champagne1, Akira Shishido, Michael J Root.   

Abstract

Cellular entry of human immunodeficiency virus type 1 (HIV-1) involves fusion of viral and cellular membranes and is mediated by structural transitions in viral glycoprotein gp41. The antiviral C-peptide T20 targets the gp41 N-terminal heptad repeat region (N-HR), blocking gp41 conformational changes essential for the entry process. To probe the T20 structure-activity relationship, we engineered a molecular mimic of the entire gp41 N-HR coiled coil using the 5-Helix design strategy. T20 bound this artificial protein (denoted 5H-ex) with nanomolar affinity (K(D) = 30 nm), close to its IC50 concentration (approximately 3 nm) but much weaker than the affinity of a related inhibitory C-peptide C37 (K(D) = 0.0007 nm). T20/C37 competitive binding assays confirmed that T20 interacts with the hydrophobic groove on the surface of the N-HR coiled coil outside of a deep pocket region crucial for C37 binding. We used 5H-ex to investigate how the T20 N and C termini contributed to the inhibitor binding activity. Mutating three aromatic residues at the T20 C terminus (WNWF --> ANAA) had no effect on affinity, suggesting that these amino acids do not participate in T20 binding to the gp41 N-HR. The results support recent evidence pointing to a different role for these residues in T20 inhibition (Peisajovich, S. G., Gallo, S. A., Blumenthal, R., and Shai, Y. (2003) J. Biol. Chem. 278, 21012-21017; Liu, S., Jing, W., Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., and Jiang, S. (2007) J. Biol. Chem. 282, 9612-9620). By contrast, mutations near the T20 N terminus substantially influenced inhibitor binding strength. When Ile was substituted for Thr in the second T20 position, a 40-fold increase in binding affinity was measured (K(D) = 0.75 nm). The effect of this affinity enhancement on T20 inhibitory potency varied among different viral strains. The original T20 and the higher affinity T20 variant had similar potency against wild type HIV-1. However, the higher affinity T20 variant was significantly more potent against T20-resistant virus. The findings suggest that other factors in addition to binding affinity play a role in limiting T20 potency. As a mimetic of the complete gp41 N-HR coiled coil region, 5H-ex will be a useful tool to further elucidate mechanistic profiles of C-peptide inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073602      PMCID: PMC2635040          DOI: 10.1074/jbc.M809269200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

2.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

3.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.

Authors:  J M Louis; C A Bewley; G M Clore
Journal:  J Biol Chem       Date:  2001-06-19       Impact factor: 5.157

5.  Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.

Authors:  Michael J Root; Dean H Hamer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

6.  C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion.

Authors:  Sergio G Peisajovich; Stephen A Gallo; Robert Blumenthal; Yechiel Shai
Journal:  J Biol Chem       Date:  2003-03-19       Impact factor: 5.157

7.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Authors:  Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

9.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

10.  Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion.

Authors:  John M Louis; Issa Nesheiwat; LengChee Chang; G Marius Clore; Carole A Bewley
Journal:  J Biol Chem       Date:  2003-03-24       Impact factor: 5.157

View more
  30 in total

1.  Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.

Authors:  Ioannis Kagiampakis; Arbi Gharibi; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Kristabelle Alatas; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

2.  Highly potent chimeric inhibitors targeting two steps of HIV cell entry.

Authors:  Bo Zhao; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Patricia J Liwang
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

3.  Kinetically coupled folding of a single HIV-1 glycoprotein 41 complex in viral membrane fusion and inhibition.

Authors:  Junyi Jiao; Aleksander A Rebane; Lu Ma; Ying Gao; Yongli Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

4.  Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.

Authors:  Gang Chen; Jonathan D Cook; Wei Ye; Jeffrey E Lee; Sachdev S Sidhu
Journal:  Protein Sci       Date:  2019-08       Impact factor: 6.725

5.  Dynamics and binding interactions of peptide inhibitors of dengue virus entry.

Authors:  Diyana Mohd Isa; Sek Peng Chin; Wei Lim Chong; Sharifuddin M Zain; Noorsaadah Abd Rahman; Vannajan Sanghiran Lee
Journal:  J Biol Phys       Date:  2019-01-24       Impact factor: 1.365

6.  Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity.

Authors:  Maarten Danial; Angela N Stauffer; Frederik R Wurm; Michael J Root; Harm-Anton Klok
Journal:  Bioconjug Chem       Date:  2016-10-27       Impact factor: 4.774

7.  HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Authors:  Kazuki Shimane; Kumi Kawaji; Fusako Miyamoto; Shinya Oishi; Kentaro Watanabe; Yasuko Sakagami; Nobutaka Fujii; Kazuya Shimura; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

8.  Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization.

Authors:  Amanda J H Gilliam; Joshua N Smith; Dylan Flather; Kevin M Johnston; Andrew M Gansmiller; Dmitry A Fishman; Joshua M Edgar; Mark Balk; Sudipta Majumdar; Gregory A Weiss
Journal:  J Med Chem       Date:  2016-04-11       Impact factor: 7.446

9.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Authors:  Kristen M Kahle; H Kirby Steger; Michael J Root
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.